- Exchanges
- BSE, NSE
- Industry
- Pharmaceuticals
- Issue
- Book building
Gland Pharma IPO
₹1,819.55
+21.30% on listing
Listing-day close · NSE · 20 Nov 2020 · issue price ₹1,500
Gland Pharma’s ₹6,480 crore IPO was priced at ₹1,500 a share. It listed on the NSE on 20 Nov 2020 and closed its first day at ₹1,819.55, up 21.30% on the issue price.
Timeline
- Opens
- Closes
- Allotment
- Refunds
- Shares in demat
- Listing
Issue details
- Issue size
- ₹6,480 Cr
- Fresh issue
- ₹1,250 Cr
- Offer for sale
- ₹5,230 Cr
- Lot size
- 10 shares
- Minimum investment
- ₹15,000
- Face value
- ₹1
- Registrar
- MUFG Intime India
Subscription
| Category | Shares offered | Times subscribed |
|---|---|---|
| Total | — | 1.72× |
Overall, from the basis of allotment.
Financials and valuation
- Market cap (post-issue)
- ₹24,492 Cr
- Promoter holding
- 74.00% → 70.22%
From the offer documents.
Listing
- Listing date
- 20 Nov 2020
- Issue price
- ₹1,500
- Open
- ₹1,710.00
- High
- ₹1,850.00
- Low
- ₹1,700.00
- Close
- ₹1,819.55
Listing day on the NSE. The close was +21.30% on the issue price.
GLAND share price todayFAQs
When did the Gland Pharma IPO open and close?
It opened on 9 Nov 2020 and closed on 11 Nov 2020.
What was the Gland Pharma IPO price?
The price band was ₹1,490–1,500 a share. The final issue price was ₹1,500.
What is the lot size and minimum investment?
One lot is 10 shares, ₹15,000 at ₹1,500 a share. Retail investors apply in whole lots.
How much did Gland Pharma raise?
₹6,480 crore: ₹1,250 crore of new shares and ₹5,230 crore offered by existing shareholders.
How many times was the Gland Pharma IPO subscribed?
1.72 times overall.
How did Gland Pharma list?
It listed on the NSE on 20 Nov 2020 at ₹1,710.00 and closed the day at ₹1,819.55, up 21.30% on the ₹1,500 issue price.
Who is the registrar of the Gland Pharma IPO?
MUFG Intime India handles the allotment, refunds and credit of shares.
For information only. Not investment advice or a research report.
Full disclaimerSee how an IPO fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app